This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Thermo Fisher's (TMO) Delta Q IRMS to Back Sustainable Science
by Zacks Equity Research
Thermo Fisher (TMO) has introduced the new Delta Q IRMS under the IsoFootprint campaign to support sustainable science by eliminating carbon dioxide emission.
Thermo Fisher (TMO) Introduces New Automated Enzyme Analyzers
by Zacks Equity Research
The two new Gallery Enzyme Master systems by Thermo Fisher (TMO) offer enhanced reliable enzyme analysis across several enterprises.
Thermo Fisher's (TMO) Oncomine Dx Gets CDx Approval for EXKIVITY
by Zacks Equity Research
Thermo Fisher (TMO) gains FDA pre-market approval for Oncomine Dx as companion diagnostic for Takeda's EXKIVITY.
Thermo Fisher's (TMO) Oncomine Dx Gets CDx Approval From MHLW
by Zacks Equity Research
Thermo Fisher's (TMO) Oncomine Dx Target Test has been approved by MHLW as a companion diagnostic for Eli Lilly and Company's selpercatinib.
Here's Why You Should Add STERIS (STE) to Your Portfolio Now
by Zacks Equity Research
STERIS (STE) ended first-quarter fiscal 2022 with better-than-expected results and strong segmental performance, driving the top line.
Zimmer Biomet (ZBH) Hurt by EMEA's Slow Recovery Amid Pandemic
by Zacks Equity Research
Zimmer Biomet's (ZBH) leveraged capital structure is an added concern.
Thermo Fisher (TMO) Gains Government Contract for Pipette Tip
by Zacks Equity Research
Thermo Fisher (TMO) will co-invest with the U.S. government to build a new manufacturing center for pipette tips in North Carolina.
Here's Why You Should Retain Integra (IART) Stock for Now
by Zacks Equity Research
Solid performance across the CSS and Tissue Technologies segments is driving the top line for Integra (IART).
Thermo Fisher's (TMO) Oncomine Dx Gets CDx Approval for TIBSOVO
by Zacks Equity Research
Thermo Fisher (TMO) receives FDA go-ahead for the Oncomine Dx Target Test as a CDx for Servier's ivosidenib tablets, TIBSOVO.
SmileDirectClub (SDC) Reels Under Rising Costs, Debt Woes
by Zacks Equity Research
SmileDirectClub (SDC) sees net operating cash outflow in the second quarter.
Teleflex (TFX) Rides on UroLift Growth, Hurt by Pandemic Woes
by Zacks Equity Research
Teleflex (TFX) has decided to increase its investment in 2021 and run a national campaign for the full year.
Globus Medical (GMED) Gets FDA Nod for Excelsius3D
by Zacks Equity Research
The receipt of FDA's 510(k) clearance for Globus Medical's (GMED) Excelsius3D is expected to expand the company's presence in the intraoperative imaging system space.
Insulet's (PODD) Omnipod Gets FDA Nod for Use With Lyumjev
by Zacks Equity Research
Insulet's (PODD) Omnipod is the only insulin pump to get approved for use with Lyumjev in the United States.
Amedisys (AMED) Suffers From Low Occupancy Amid Pandemic
by Zacks Equity Research
The prolonged and lingering impact of COVID-19 on Amedisys (AMED) Hospice business has hampered its ability to grow at the earlier-projected rates.
Thermo Fisher (TMO) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance by the four reported business segments is driving the top line for Thermo Fisher (TMO).
Semler Scientific Inc. (SMLR) Q2 Earnings Top Estimates
by Zacks Equity Research
Semler Scientific Inc. (SMLR) delivered earnings and revenue surprises of 36.07% and -1.51%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Semler Scientific Inc. (SMLR) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Semler Scientific Inc. (SMLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Semler Scientific Inc. (SMLR) Soars 4.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Semler Scientific Inc. (SMLR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Orthofix (OFIX) Launches FORZA Ti PLIF Spacer System in the US
by Zacks Equity Research
Orthofix (OFIX) launches FORZA Ti PLIF Spacer System to improve posterior lumbar interbody fusion procedures in the United States.
What Makes Semler Scientific Inc. (SMLR) a New Buy Stock
by Zacks Equity Research
Semler Scientific Inc. (SMLR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
3 Reasons Why Semler Scientific Inc. (SMLR) Is a Great Growth Stock
by Zacks Equity Research
Semler Scientific Inc. (SMLR) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Orthofix (OFIX) Launches OSCAR PRO System in the US & Europe
by Zacks Equity Research
Orthofix's (OFIX) latest innovation is expected to drive organic growth in its Global Orthopedics business.
3 Reasons Growth Investors Will Love Semler Scientific Inc. (SMLR)
by Zacks Equity Research
Semler Scientific Inc. (SMLR) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Semler Scientific Inc. (SMLR) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Semler Scientific Inc. (SMLR) delivered earnings and revenue surprises of 22.45% and 10.32%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
3 Reasons Why Semler Scientific Inc. (SMLR) Is a Great Growth Stock
by Zacks Equity Research
Semler Scientific Inc. (SMLR) could produce exceptional returns because of its solid growth attributes.